T helper 1 and T helper 2 cells are pathogenic in an antigen-specific model of colitis

被引:119
作者
Iqbal, N
Oliver, JR
Wagner, FH
Lazenby, AS
Elson, CO
Weaver, CT
机构
[1] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35233 USA
[2] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35233 USA
关键词
inflammatory bowel disease; E; coli; CD4; cytokines; TCR transgenic;
D O I
10.1084/jem.2001889
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Dysregulated T cell responses to enteric bacteria have been implicated as a common mechanism underlying pathogenesis in rodent models of colitis. However, the bacterial species and T cell specificities that induce disease have been poorly defined. We have developed a model system in which target antigen, bacterial host, and corresponding T cell specificity are defined. OVA-specific T cells from DO11.RAG-2(-/-) TCR transgenic mice were transferred into RAG-2(-/-) recipients whose intestinal tracts were colonized with OVA-expressing or control Escherichia coli. Transfer of antigen-naive DO11.RAG-2(-/-) T cells into recipients colonized with OVA-E. coli resulted in enhanced intestinal recruitment and cell cycling of OVA-specific T cells, however, there was no development of disease. In contrast, transfer of polarized T helper (Th) 1 and Th2 populations resulted in severe wasting and colitis in recipients colonized with OVA-expressing but not control E. coli. The histopathologic features of disease induced by Th1 and Th2 transfers were distinct, but disease severity was comparable. Induction of disease by both Th1 and Th2 transfers was dependent on bacterially associated OVA. These results establish that a single bacterially associated antigen can drive the progression of colitis mediated by both Th1 and Th2 cells and provide a new model for understanding the immunoregulatory interactions between T cells responsive to gut floral antigens.
引用
收藏
页码:71 / 84
页数:14
相关论文
共 61 条
  • [1] Aranda R, 1997, J IMMUNOL, V158, P3464
  • [2] Colitis in transgenic and knockout animals as models of human inflammatory bowel disease
    Bhan, AK
    Mizoguchi, E
    Smith, RN
    Mizoguchi, A
    [J]. IMMUNOLOGICAL REVIEWS, 1999, 169 : 195 - 207
  • [3] Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4
    Boirivant, M
    Fuss, IJ
    Chu, A
    Strober, W
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (10) : 1929 - 1939
  • [4] Brandwein SL, 1997, J IMMUNOL, V159, P44
  • [5] Inhibition of pulmonary eosinophilia in P-selectin- and ICAM-1-deficient mice
    Broide, DH
    Sullivan, S
    Gifford, T
    Sriramarao, P
    [J]. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 1998, 18 (02) : 218 - 225
  • [6] SINGLE-CELL ANALYSIS OF CYTOKINE GENE COEXPRESSION DURING CD4(+) T-CELL PHENOTYPE DEVELOPMENT
    BUCY, RP
    KARR, L
    HUANG, GQ
    LI, JM
    CARTER, D
    HONJO, K
    LEMONS, JA
    MURPHY, KM
    WEAVER, CT
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (16) : 7565 - 7569
  • [7] Inflammatory bowel disease: An immunity-mediated condition triggered by bacterial infection with Helicobacter hepaticus
    Cahill, RJ
    Foltz, CJ
    Fox, JG
    Dangler, CA
    Powrie, F
    Schauer, DB
    [J]. INFECTION AND IMMUNITY, 1997, 65 (08) : 3126 - 3131
  • [8] USE OF THE NIRB PROMOTER TO DIRECT THE STABLE EXPRESSION OF HETEROLOGOUS ANTIGENS IN SALMONELLA ORAL VACCINE STRAINS - DEVELOPMENT OF A SINGLE-DOSE ORAL TETANUS VACCINE
    CHATFIELD, SN
    CHARLES, IG
    MAKOFF, AJ
    OXER, MD
    DOUGAN, G
    PICKARD, D
    SLATER, D
    FAIRWEATHER, NF
    [J]. BIO-TECHNOLOGY, 1992, 10 (08): : 888 - 892
  • [9] Chen ZM, 1998, J IMMUNOL, V160, P3462
  • [10] CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice:: Increased T helper cell type 1 response and ability to transfer disease
    Cong, YZ
    Brandwein, SL
    McCabe, RP
    Lazenby, A
    Birkenmeier, EH
    Sundberg, JP
    Elson, CO
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (06) : 855 - 864